Premium
Plasma proteomics can discriminate isolated early from dual responses in asthmatic individuals undergoing an allergen inhalation challenge
Author(s) -
Singh Amrit,
Cohen Freue Gabriela V.,
Oosthuizen Jean L.,
Kam Sarah H. Y.,
Ruan Jian,
Takhar Mandeep K.,
Gauvreau Gail M.,
O'Byrne Paul M.,
FitzGerald J. Mark,
Boulet LouisPhilippe,
Borchers Christoph H.,
Tebbutt Scott J.
Publication year - 2012
Publication title -
proteomics – clinical applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 54
eISSN - 1862-8354
pISSN - 1862-8346
DOI - 10.1002/prca.201200013
Subject(s) - asthma , inhalation , allergen , proteome , immunology , medicine , proteomics , allergy , bioinformatics , biology , anesthesia , biochemistry , gene
Purpose This proteomics study was designed to determine the utility of i TRAQ MALDI ‐ TOF / TOF technology to compare plasma samples from carefully phenotyped mild, atopic asthma subjects undergoing allergen inhalation challenge. Experimental design Eight adult subjects with mild, allergic asthma (four early responders (ERs) and four dual responders (DRs)) participated in the allergen inhalation challenge. Blood samples were collected prior to and 2 h after the inhalation challenge. Sixteen plasma samples (two per subject), technical replicates, and pooled controls were analyzed using i TRAQ . Technical validation was performed using LC ‐ MRM / MS . Moderated robust regression was used to determine differentially expressed proteins. Results Although this study did not show significant differences between pre‐ and post‐challenge samples, discriminant analysis indicated that certain proteins responded differentially to allergen challenge with respect to responder type. At pre‐challenge, fibronectin was significantly elevated in DR s compared to ER s and remained significant in the multiple reaction monitoring validation. Conclusions and clinical relevance This proof of principle demonstration has shown that i TRAQ can uncover differences in the human plasma proteome between two endotypes of asthma and merits further application of i TRAQ to larger cohorts of asthma and other respiratory diseases.